Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cost-cutting with albufuse
April 2008
SHARING OPTIONS:

The technology licensed by CSL Behring from Novozymes, albufuse, has value in cutting costs in the drug discovery and development process, the companies note in announcing their latest deal (see "Extending half-lives, cutting costs for proteins").

The combined expression and production process of albufuse eliminates the need for additional post-production chemical derivatization, they say, such as PEGylation methods, which are expensive and time-consuming.

"This license further demonstrates Novozymes' long-term commitment to becoming a strategic partner to the global pharmaceutical industry," notes Dr. David Mead, Novozymes' U.K. business development director.

"The applications of albufuse technology are substantial and growing, with one of our licensee's initiating a Phase III clinical trial with their interferon-based fusion candidate. We are confident that the license with CSL Behring will further demonstrate that albufuse is a key technology for drug development."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.